88 related articles for article (PubMed ID: 24304421)
1. Prospective analysis of low-level BCR-ABL1 T315I mutation in CD34 + cells of patients with de novo chronic myeloid leukemia.
Jurcek T; Razga F; Mazancova P; Musilova M; Dvorakova D; Borsky M; Zackova D; Dobesova B; Semerad L; Mayer J; Racil Z
Leuk Lymphoma; 2014 Aug; 55(8):1915-7. PubMed ID: 24304421
[No Abstract] [Full Text] [Related]
2. A pyrosequencing-based test for detection and relative quantification of the BCR-ABL1 T315I point mutation.
Schumacher JA; Szankasi P; Bahler DW; Ho AK; Kelley TW
J Clin Pathol; 2011 Jul; 64(7):618-25. PubMed ID: 21486895
[TBL] [Abstract][Full Text] [Related]
3. The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy.
Malcikova J; Razga F; Jurcek T; Dvorakova D; Zackova D; Toskova M; Sebejova L; Smardova J; Oltova A; Vankova G; Jurackova L; Trbusek M; Pospisilova S; Mayer J; Racil Z
Leuk Lymphoma; 2013 Sep; 54(9):2083-7. PubMed ID: 23289360
[No Abstract] [Full Text] [Related]
4. Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia.
Baer C; Kern W; Koch S; Nadarajah N; Schindela S; Meggendorfer M; Haferlach C; Haferlach T
Haematologica; 2016 Jul; 101(7):830-8. PubMed ID: 27102501
[TBL] [Abstract][Full Text] [Related]
5. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.
Soverini S; Branford S; Nicolini FE; Talpaz M; Deininger MW; Martinelli G; Müller MC; Radich JP; Shah NP
Leuk Res; 2014 Jan; 38(1):10-20. PubMed ID: 24131888
[TBL] [Abstract][Full Text] [Related]
6. Biological effects of T315I-mutated BCR-ABL in an embryonic stem cell-derived hematopoiesis model.
Melkus M; Bennaceur-Griscelli A; Valogne Y; Flamant S; Chomel JC; Sorel N; Bonnet ML; Deininger MW; Mitjavila-Garcia MT; Turhan AG
Exp Hematol; 2013 Apr; 41(4):335-45.e3. PubMed ID: 23287417
[TBL] [Abstract][Full Text] [Related]
7. BCR-ABL1 T315I mutation, a negative prognostic factor for the terminal phase of chronic myelogenous leukemia treated with first- and second-line tyrosine kinase inhibitors, might be an indicator of allogeneic stem cell transplant as the treatment of choice.
Tomuleasa C; Dima D; Frinc I; Patiu M; Petrushev B; Cucuianu A; Berindan-Neagoe I
Leuk Lymphoma; 2015 Feb; 56(2):546-7. PubMed ID: 25012945
[No Abstract] [Full Text] [Related]
8. Quantitative monitoring of the T315I mutation in patients with chronic myeloid leukemia (CML).
Chomel JC; Sorel N; Bonnet ML; Bertrand A; Brizard F; Saulnier PJ; Roy L; Guilhot F; Turhan AG
Leuk Res; 2009 Apr; 33(4):551-5. PubMed ID: 18829107
[TBL] [Abstract][Full Text] [Related]
9. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K
Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603
[TBL] [Abstract][Full Text] [Related]
10. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
Moore FR; Yang F; Press RD
Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
[TBL] [Abstract][Full Text] [Related]
11. New mutation L324M in the ABL1 kinase domain: does it confer high resistance to second-generation inhibitors?
Noriega MF; Ferri CA; Icardi G; Bullorsky E; Korin J; Larripa I
Leuk Lymphoma; 2014 Mar; 55(3):698-701. PubMed ID: 23741973
[No Abstract] [Full Text] [Related]
12. Deep molecular response by IFN-α and dasatinib combination in a patient with T315I-mutated chronic myeloid leukemia.
Zhou L; Shi H; Jiang S; Ruan C; Liu H
Pharmacogenomics; 2016 Jul; 17(10):1159-1163. PubMed ID: 27347777
[TBL] [Abstract][Full Text] [Related]
13. A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia.
Woessner DW; Eiring AM; Bruno BJ; Zabriskie MS; Reynolds KR; Miller GD; O'Hare T; Deininger MW; Lim CS
Leukemia; 2015 Aug; 29(8):1668-75. PubMed ID: 25721898
[TBL] [Abstract][Full Text] [Related]
14. Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex.
Chen M; Turhan AG; Ding H; Lin Q; Meng K; Jiang X
Oncotarget; 2017 Jul; 8(27):43662-43677. PubMed ID: 28599273
[TBL] [Abstract][Full Text] [Related]
15. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS
Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a novel variant BCR-ABL1 fusion transcript in a patient with chronic myeloid leukemia: Implications for molecular monitoring.
Crampe M; Haslam K; Kelly J; Conneally E; Langabeer SE
Hematol Oncol Stem Cell Ther; 2017 Jun; 10(2):85-88. PubMed ID: 27013275
[TBL] [Abstract][Full Text] [Related]
17. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
[TBL] [Abstract][Full Text] [Related]
18. The incidence of co-existing BCR-ABL1 and JAK2 V617F rearrangements: implications for molecular diagnostics.
McCarron SL; Haslam K; Crampe M; Langabeer SE
Lab Hematol; 2012 Dec; 18(4):20-1. PubMed ID: 23253862
[No Abstract] [Full Text] [Related]
19. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
20. Treatment of an adolescent with chronic myeloid leukemia and the T315I mutation with ponatinib.
Nickel RS; Daves M; Keller F
Pediatr Blood Cancer; 2015 Nov; 62(11):2050-1. PubMed ID: 25939962
[No Abstract] [Full Text] [Related]
[Next] [New Search]
